Medical writer: Dave Levitan
The novel selective RET inhibitor BLU-667 demonstrated promising anti-tumour activity and was well tolerated in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC), according to a study presented on June 3 (Abstract 9008).
Approximately 1% to 2% of patients with NSCLC have tumours harboring RET fusions. “In contrast to other oncogenic fusions in NSCLC, such as ALK…there are currently no [U.S. Food and Drug Administration (FDA)]–approved selective RET inhibitors to date,” Justin F. Gainor, MD, of Massachusetts General Hospital, said, during the presentation of the results of the ongoing ARROW phase I dose-escalation and expansion study.
Patients with NSCLC have had low response rates to chemotherapy and immune checkpoint inhibition, and multikinase inhibitors have demonstrated low activity and high levels of off-target toxicity. BLU-667 potently and selectively inhibits ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Lurbinectedin Shows Promise as Second-line Therapy for SCLC Next Article
Laparascopic Surgery; Less Morbidity, Same Survival Benefits as Open Surgery in Colorectal Cancer with Liver Metastases »
Table of Contents: ASCO 2019
Head and Neck Cancer
Genitourinary Cancer - Prostate Cancer
Developmental Therapeutics - Immunotherapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.